When Bhenobarbital pharma grade API is specified for direct compression, the first process decision is not chemical purity but whether the supplied particle-size distribution and flow indices can sustain high-speed rotary compression without segregation. Direct-compression-grade Bhenobarbital is typically controlled with a D90 no greater than 150 µm, a D10 no lower than 10 µm, bulk density between 0.35 g/cm³ and 0.55 g/cm³, tapped density between 0.50 g/cm³ and 0.75 g/cm³, and a Hausner ratio below 1.35. If the as-received API exceeds a Carr index of 25 or the fine fraction below 50 µm exceeds 20% w/w, direct compression is discontinued in favour of slugging or wet granulation because fill-weight variability on a 27-station rotary press can move beyond 3% RSD at turret speeds above 40 rpm. The compression blend is commonly formulated with Bhenobarbital at 15%–30% w/w, microcrystalline cellulose at 40%–60% w/w, lactose monohydrate at 20%–40% w/w, crospovidone at 2%–5% w/w, and magnesium stearate at 0.25%–1.0% w/w. The API is first passed through a 600 µm sieve with the free-flowing diluents and disintegrant to break down loose agglomerates; the lubricant is added in a final blending step not exceeding 5 minutes at 15–25 rpm because overlubrication produces punch filming and delayed disintegration. Compression force is maintained between 8 kN and 18 kN for 12 mm round flat-faced bevel-edge tooling, yielding tablets with crushing strength 60–120 N, friability below 0.5%, disintegration time under 15 minutes in 900 mL water at 37 °C per Ph. Eur. 2.9.1, and content uniformity acceptance value ≤ 15 per Ph. Eur. 2.9.40 or USP <905>. Dissolution is provisionally evaluated in 0.1 M hydrochloric acid using paddle apparatus at 75 rpm, with Q = 75% released in 45 minutes as a conventional immediate-release target; published data for this specific Bhenobarbital configuration is limited, so the criterion must be verified against the approved target product profile. Segregation control depends on stepwise geometric blending rather than one-step bin blending, and some lines use in-line near-infrared monitoring across 1250–2400 nm to detect active-concentration drift before compression.

Production-scale failure modes observed on direct-compression lines include sticking of Bhenobarbital to upper punch faces when lubricant is poorly dispersed or when dwell time exceeds 50 ms; picking becomes more frequent at tablet thickness below 3.0 mm and when the API contains a significant sub-50 µm fraction. Chromium nitride or nano-ceramic tooling coatings reduce the frequency of picking, but they do not replace a lubricant design-of-experiments matrix across 0.25%, 0.50%, and 1.0% w/w magnesium stearate. The terminal product is a compact immediate-release tablet, often debossed for traceability, which may be film-coated with an aqueous Opadry system at 2%–4% w/w weight gain after compression provided the inlet air temperature is controlled at 60–70 °C and the tablet-bed temperature does not exceed 45 °C to avoid moisture-mediated or polymorphic alteration.

What Limits Fill Weight in Low-Dose Bhenobarbital Capsule Operations?

Low-fill-weight encapsulation of Bhenobarbital in hard gelatin or hypromellose capsules is limited not by the intrinsic potency of the API but by flow, dusting, and segregation characteristics of the pre-blend. When filling a size 0 capsule with 30 mg Bhenobarbital and a target fill weight of 180 mg, the active represents 16.7% w/w of the blend; for a 15 mg strength at the same fill weight, the fraction falls to 8.3% w/w and the likelihood of content non-uniformity rises on tamping-pin machines. The pre-blend typically consists of Bhenobarbital passed through a 400 µm screen, pregelatinized starch at 20%–35% w/w, lactose monohydrate at 40%–55% w/w, croscarmellose sodium at 2%–4% w/w, and sodium stearyl fumarate at 0.5%–1.0% w/w as an alternative lubricant when higher mechanical discrimination is required. A dosator-type capsule filler with 10–16 stations is operated at 6000–18000 capsules/hour depending on powder bed height and tamping-pin compression settings; an auger or vacuum-assisted feed system is preferred for low-dose formulations to maintain blend fluidity. Weight uniformity is checked at 5–10 minute intervals, and the acceptance criterion for individual capsule fill weight is ± 5% of target with content uniformity acceptance value ≤ 15 as specified in Ph. Eur. 2.9.40 or USP <905>. Dissolution is measured using rotating basket or paddle apparatus at 75 rpm in 0.1 M hydrochloric acid, while shell rupture time is separately confirmed by the disintegration method in Ph. Eur. 2.9.1 or USP <2040>. For hard gelatin capsules, shell moisture is held below 13% w/w; for hypromellose capsules, moisture is kept below 7% w/w because higher levels cause shell softening and cross-linking-related dissolution slowdown. The significant operational boundary is that Bhenobarbital should not be co-milled with highly hygroscopic excipients such as sorbitol or xylitol in unsealed powder hoppers above 60% relative humidity, because moisture uptake can dissolve the API and promote caking. Finished capsules are passed through a metal detector with ferrous, non-ferrous, and stainless-steel sensitivity not exceeding 0.5 mm sphere equivalent, then dedusted and packed in PVC/aluminum blisters. Batch release includes identity, assay, related substances, dissolution, content uniformity, and microbiological quality as required by Ph. Eur. 5.1.4 or USP <1111> depending on the filing jurisdiction. The limiting parameter is usually blend stratification after long hopper residence times; after 30 minutes of continuous operation, samples from the feed shoe should not exceed 2% deviation from the target API assay.

When Wet Granulation Is Selected over Direct Compression for Bhenobarbital Tablets

Wet granulation is selected when Bhenobarbital must be compressed at doses below 10 mg per tablet, or when an API lot has a Hausner ratio above 1.45 and cannot be reliably direct-compressed. The active is dispersed into a pre-mix of microcrystalline cellulose, lactose monohydrate, and pregelatinized starch before aqueous binder addition; typical binder is povidone K30 at 2.0%–5.0% w/w total granulate mass, dissolved in purified water to a concentration of 5%–10% w/v. Granulation water quantity is usually 20%–35% w/w of the dry powder bed and is added at 2–4 mL/min/kg in a high-shear granulator with impeller tip speed 4–6 m/s and chopper speed 1500–3000 rpm. Endpoint is determined by power draw or torque inflection instead of fixed time; an impeller current increase of 20%–35% from the dry-mix baseline correlates with granule median particle size 150–400 µm. The wet mass is discharged through a 6.3 mm grate into a fluid-bed dryer set to 55–65 °C inlet air and dried to loss on drying 1.5%–3.0% w/w as measured by halogen moisture balance at 105 °C. Dried granules are milled through a 0.8–1.6 mm screen in a conical or oscillating granulator, then blended with crospovidone at 2%–5% w/w and magnesium stearate at 0.5%–1.0% w/w. Compression force on a rotary press is generally 10–20 kN, producing tablets with hardness 50–100 N and disintegration times below 15 minutes. Because wet granulation introduces water and heat, the API must be thermally stable at the drying temperature; forced degradation studies at 60 °C and 75% RH for 14 days are typically required to confirm that no new degradation product above the qualification threshold 0.2% appears. The terminal tablet is usually film-coated with an aqueous ethylcellulose or polyvinyl alcohol-based system, and dissolution is performed in pH 1.2 or pH 6.8 media. Granule size is the principal critical material attribute; if the fraction above 850 µm exceeds 20% w/w, tablet content uniformity worsens because coarse granules are diluent-rich and the fine fraction is API-rich. Sieve analysis is therefore performed on each batch using 125 µm, 250 µm, 500 µm, and 850 µm screens per Ph. Eur. 2.9.38 or USP <786>. Scale-up should not assume geometric similarity with high-shear granulation beyond a 50 L bowl volume without mixing-energy-per-unit-mass calculations because impeller torque is not linearly scalable at 300 L and above.

For injectable solution manufacturing, Bhenobarbital free acid is converted to the sodium salt because the free acid solubility in water at 25 °C is insufficient for a parenteral product. The sodium salt permits formulation at 30–130 mg/mL, and the vehicle commonly contains propylene glycol at 70%–90% v/v and water for injection at 10%–30% v/v, with sodium hydroxide or sodium carbonate added to adjust pH to 9.0–10.5. pH variation beyond 10.5 accelerates glass vial delamination at the inner surface, while pH below 8.5 risks precipitation of the free acid. The solution is prefiltered through a 0.45 µm membrane and sterile-filtered through a 0.22 µm PVDF or PES filter in a nitrogen-blanketed vessel; filling is performed in an ISO 14644-1:2015 Grade A zone with Grade B background. Terminal sterilisation at 121 °C for 15 minutes with F0 ≥ 8 minutes is used where stability data demonstrate acceptable degradation; otherwise aseptic filtration is applied. Sub-visible particle testing must meet USP <788> limits for small-volume injections: not more than 6000 particles ≥ 10 µm and not more than 600 particles ≥ 25 µm per container. Endotoxin is controlled to 0.5 EU/mg or a stricter limit derived from the clinical dose, and sterility is confirmed by Ph. Eur. 2.6.1 or USP <71>. The finished solution is filled into amber type-I borosilicate glass vials or ampoules under nitrogen, stoppered with bromobutyl rubber closures, and sealed with aluminium caps. Contact with silicone oil-lubricated piston systems should be limited because the alkaline pH can extract silicone oligomers during extended storage. The terminal product is stored below 25 °C and protected from light.

Lyophilised Bhenobarbital Sodium for Reconstitution: Collapse, Cake Structure, and Residual Moisture

When aqueous solution stability data for Bhenobarbital sodium fail to support a ready-to-use injectable, lyophilised presentations are selected to provide a dry-powder product with longer shelf life. The freeze-drying formulation generally contains Bhenobarbital sodium at 30–60 mg/mL before filling, with mannitol or lactose monohydrate as a bulking agent at 2%–5% w/v. The solution is filled into 10 mL type-I moulded glass vials at a fill volume of 2–5 mL, then semi-stoppered for lyophilisation. Freezing is conducted on stainless-steel shelves pre-cooled to -40 °C at a ramp rate of 0.5–1.0 °C/min, followed by a hold of 2–4 hours to ensure complete solidification. Primary drying shelf temperature is ramped to -10 °C to 0 °C under chamber pressure 80–120 µbar; product temperature must remain below the collapse temperature during sublimation, which for mannitol-based barbiturate formulations is typically in the range of -25 °C to -15 °C as measured by freeze-drying microscopy. Secondary drying is run at 30–40 °C for 6–10 hours to bring residual moisture below 1.0% w/w by Karl Fischer titration. Cake appearance is inspected for shrinkage, meltback, or collapse; a uniform white to off-white cake with no visible collapse is the acceptance criterion for release. Residual moisture above 1.5% w/w shortens re-suspendability time and increases hydrolytic degradation upon storage. The reconstituted solution must be clear and free from visible particles after dilution with 10 mL water for injection, and the pH should be 9.0–10.5. Sub-visible particle testing follows Ph. Eur. 2.9.19 or USP <788>; container-closure integrity is confirmed by vacuum decay or dye ingress using methods aligned with USP <1207>. Vial headspace moisture and oxygen are controlled by backfilling with nitrogen to 0.4–0.6 bar before stoppering. The main scale-up failure is edge-vial freezing heterogeneity; when the shelf is loaded edge-to-edge with more than 2000 vials per batch, the cold zone near the condenser can produce a temperature difference of 3–5 °C across the shelf, leading to partial meltback in the front row unless drying cycles are extended by 10%–15%.

Bhenobarbital Granules for Sachet Filling and Suspension Reconstitution

For oral sachet and dry syrup reconstitution, Bhenobarbital granules are designed to suspend rather than compress, so the disintegrant fraction is reduced or omitted and thickeners such as xanthan gum at 0.05%–0.20% w/w or hypromellose at 0.5%–2.0% w/w are incorporated. Sucrose or mannitol serves as the main diluent at 70%–90% w/w; Bhenobarbital is dispersed at 5–20 mg/g in the final granule, giving a dose-to-granule ratio of 1:10 to 1:50. The API and diluents are granulated with a hydroalcoholic binder of povidone K30 in 50% ethanol at 2%–4% w/w, and the wet mass is extruded through a 0.8 mm screen and spheronised at 800–1200 rpm for 3–5 minutes to produce pellets with median size 600–850 µm. Drying is carried out in a fluid-bed at 45–55 °C to moisture below 1.0% w/w because low-melting sugars can caramelise at higher temperatures. The sachet is filled by a volumetric auger filler with fill weight tolerance ± 3%; sealing temperature for laminated aluminium foil is 140–160 °C with dwell time 0.5–1.0 seconds. Upon reconstitution, suspension viscosity at 25 °C is 100–300 mPa·s at a shear rate of 10 s⁻¹, sufficient to retard sedimentation without preventing pour-out. Dissolution testing is performed in pH 6.8 phosphate buffer using the paddle apparatus at 50 rpm, with acceptance criterion Q = 80% released in 30 minutes only if justified by biowaiver or comparative data; otherwise the generated dissolution method must be pharmacopeially validated. The finished product is packed in single-dose or multi-dose sachets with desiccant in the outer carton; moisture uptake after 6 months at 40 °C/75% RH should not exceed 0.5% w/w. Microbiological quality for oral liquids is confirmed by absence of Escherichia coli in 1 g per Ph. Eur. 5.1.4 or USP <62>. A distinct operational boundary is the incompatibility of Bhenobarbital granules with strongly acidic fruit juices used for reconstitution; at pH below 3.5, the API may precipitate or interact with pectin, and therefore only water is used for dose administration.